ToffCap’s Monday Monitor #75Kezar Life Sciences, Inc. – KZR
Pitch Summary: Kezar Life Sciences is reviewing strategic alternatives for its Zetomipzomib Program, with the potential for liquidation, following a rejected acquisition offer and recent share price increase. BSD Analysis: Kezar Life Sciences’ decision to explore strategic alternatives for its Zetomipzomib Program comes amid financial challenges, with a negative enterprise value and significant cash reserves […]
